Targeting Norepinephrine Transporters in Cardiac Sympathetic Nerve Terminals

Targeted Molecular Imaging

Volumn , Issue , 2012, Pages 305-320

  Raffel, David M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885011763     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b11628-28     Document Type: Chapter

References (86)

1. Allman, K. C., Wieland, D. M., Muzik, O., Degrado, T. R., Wolfe, E. R., and Schwaiger, M. 1993. Carbon-11 hydroxyephedrine with positron emission tomography for serial assessment of cardiac adrenergic neuronal function after acute myocardial infarction in humans. J. Am. Coll. Cardiol. 22: 368-75.
2. Armour, J. A. 1998. Myocardial ischaemia and the cardiac nervous system. Cardiovasc. Res. 41: 41-54.
3. Bengel, F. M., Überfuhr, P., Ziegler, S. I., Nekolla, S., Reichart, B., and Schwaiger, M. 1999. Serial assessment of sympathetic reinnervation after orthotopic heart transplantation. Circulation 99: 1866-71.
4. Böhm, M., Castellano, M., Flesch, M. et al. 1998. Chamber-specific alterations of norepinephrine uptake sites in cardiac hypertrophy. Hypertension 32: 831-37.
5. Böhm, M., La Rosée, K., Schwinger, R. H. G., and Erdmann, E. 1995. Evidence for reduction of norepinephrine uptake sites in the failing human heart. J. Am. Coll. Cardiol. 25: 145-53.
6. Burgen, A. S. V. and Iversen, L. L. 1965. The inhibition of noradrenaline uptake by sympathomimetic amines in the rat isolated heart. Br. J. Pharmacol. 25: 34-49.
7. Carr, E. A., Carroll, M., Counsell, R. E., and Tyson, J. W. 1979. Studies of uptake of the bretylium analogue, iodobenzyltrimethylammonum iodide, by non-primate, monkey and human heart. Br. J. Clin. Pharmacol. 8: 425-32.
8. Cornelissen, J., Van Kuilenburg, A. B. P., Voûte, P. A., and Van Gennip, A. H. 1997. The effect of the neuroblastoma-seeking agent meta-iodobenzylguanidine (MIBG) on NADH-driven superoxide formation and NADH-driven lipid peroxidation in beef heart submitochondrial particles. Eur. J. Cancer 33: 421-24.
9. Croteau, E., Bénard, F., Bentourkia, M., Rousseau, J., Paquette, M., and Lecomte, R. 2004. Quantitative myocardial perfusion and coronary reserve in rats with 13N-ammonia and small animal PET: Impact of anesthesia and pharmacologic stress agents. J. Nucl. Med. 45: 1924-30.
10. Dae, M. W., De Marco, T., Botvinick, E. H. et al. 1992. Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts-Implications for clinical studies. J. Nucl. Med. 33: 1444-50.
11. DeGrado, T. R., Hutchins, G. D., Toorongian, S. A., Wieland, D. M., and Schwaiger, M. 1993. Myocardial kinetics of carbon-11-meta-hydroxyephedrine: Retention mechanisms and effects of norepinephrine. J. Nucl. Med. 34: 1287-93.
12. DeGrado, T. R., Zalutsky, M. R., Coleman, R. E., and Vaidyanathan, G. 1998. Effects of specific activity on meta-[131I]iodobenzylguanidine kinetics in isolated rat heart. Nucl. Med. Biol. 25: 59-64.
13. DeGrado, T. R., Zalutsky, M. R., and Vaidyanathan, G. 1995. Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart. Nucl. Med. Biol. 22: 1-12.
14. Deussen, A., Flesche, C. W., Lauer, T., Sonntag, M., and Schrader, J. 1996. Spatial heterogeneity of blood flow in the dog heart. II. Temporal stability in response to adrenergic stimulation. Pflügers Arch. Eur. J. Physiol. 432: 451-61.
15. Dischino, D. D., Welch, M. J., Kilbourn, M. R., and Raichle, M. E. 1983. Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J. Nucl. Med. 24: 1030-38.
16. Donovan, A. C. and Valliant, J. F. 2008. A convenient solutionphase method for the preparation of meta-iodobenzylguanidine in high effective specific activity. Nucl. Med. Biol. 35: 741-46.
17. Eisenhofer, G., Smolich, J. J., and Esler, M. D. 1992. Disposition of endogenous adrenaline compared to noradrenaline released by cardiac sympathetic nerves in the anaesthetized dog. Naunyn-Schmiedeberg’s Arch. Pharmacol. 345: 160-71.
18. Estorch, M., Carrió, I., Mena, E. et al. 2004. Challenging the neuronal MIBG uptake by pharmacological intervention: Effect of a single dose of oral amitriptyline on regional cardiac MIBG uptake. Eur. J. Nucl. Med. Mol. Imaging 31: 1575-80.
19. Ewing, D. J. 1996. Diabetic autonomic neuropathy and the heart. Diabetes Res. Clin. Pract. 30(Suppl): 31-36.
20. Farahati, J., Bier, D., Scheubeck, M. et al. 1997. Effect of specific activity on cardiac uptake of iodine-123-MIBG. J. Nucl. Med. 38: 447-51.
21. Flotats, A. and Carrió, I. 2004. Cardiac neurotransmission SPECT imaging. J. Nucl. Cardiol. 11: 587-602.
22. Gaze, M. N., Huxham, I. M., Mairs, R. J., and Barrett, A. 1991. Intracellular localization of metaiodobenzylguanidine in human neuroblastoma cells by electron spectroscopic imaging. Int. J. Cancer 47: 875-80.
23. Glowniak, J., Turner, F., Gray, L., Palac, R., Lagunas-Solar, M., and Woodward, W. 1989. Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants. J. Nucl. Med. 30: 1182-91.
24. Graefe, K.-H. 1981. The disposition of 3H-(-)-noradrenaline in the perfused cat and rabbit heart. Naunyn-Schmiedeberg’s Arch. Pharmacol. 318: 71-82.
25. Graefe, K.-H., Bönisch, H., and Keller, B. 1978. Saturation kinetics of the adrenergic neurone uptake system in the perfused rabbit heart: A new method for determination of initial rates of amine uptake. Naunyn-Schmiedeberg’s Arch. Pharmacol. 302: 263-73.
26. Henneman, M. M., Bengel, F. M., van der Wall, E. E., Knuuti, J., and Bax, J. J. 2008. Cardiac neuronal imaging: Application in the evaluation of cardiac disease. J. Nucl. Cardiol. 15: 442-55.
27. Higuchi, T. and Schwaiger, M. 2006. Imaging cardiac neuronal function and dysfunction. Curr. Cardiol. Rep. 8: 131-38.
28. Hutchins, G. D. and Schwaiger, M. 1993. In Nuclear Cardiology: State of the Art and Future Directions (Eds, Zaret, B. L. and Beller, G. A.) Mosby, St. Louis, MO, pp. 305-13.
29. Iversen, L. L. 1965. The uptake of catechol amines at high perfusion concentrations in the rat isolated heart: A novel catechol amine uptake process. Br. J. Pharmacol. 25: 18-33.
30. Jacobson, A. F., Senior, R., Cerqueira, M. D. et al. 2010. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure: Results of the prospective ADMIRE-HF (AdreView myocardial imaging for risk evaluation in heart failure) study. J. Am. Coll. Cardiol. 55: 2212-21.
31. Jewett, D. M. 1992. A simple synthesis of [11C]-methyl triflate. Appl. Radiat. Isot. 43: 1383-85.
32. Kingwell, B. A., Thompson, J. M., Kaye, D. M., McPherson, G. A., Jennings, G. L., and Esler, M. D. 1994. Heart rate spectral analysis, cardiac norepinephrine spillover, and muscle sympathetic nerve activity during human sympathetic nervous activation and failure. Circulation 90: 234-40.
33. Kiyono, Y., Iida, Y., Kawashima, H., Tamaki, N., Nishimura, H., and Saji, H. 2001. Regional alterations of myocardial norepinephrine transporter density in streptozotocin-induced diabetic rats: Implications for heterogeneous cardiac accumulation of MIBG in diabetes. Eur. J. Nucl. Med. 38: 894-99.
34. Kiyono, Y., Kanegawa, N., Kawashima, H. et al. 2002. Age-related changes of myocardial norepinephrine transporter density in rats: Implications for differential cardiac accumulation of MIBG in aging. Nucl. Med. Biol. 29: 679-84.
35. Lautamäki, R., Tipre, D., and Bengel, F. M. 2007. Cardiac sympathetic neuronal imaging using PET. Eur. J. Nucl. Med. Mol. Imaging 34: S74-S85.
36. Law, M. P., Osman, S., Davenport, R. J., Cunningham, V. J., Pike, V. W., and Camici, P. G. 1997. Biodistribution and metabolism of [N-methyl-11C]-m-hydroxyephedrine in the rat. Nucl. Med. Biol. 24: 417-24.
37. Leitz, F. H. and Stefano, F. J. E. 1971. The effect of tyramine, amphetamine and metaraminol on the metabolic disposition of 3H-norepinephrine released from the adrenergic neuron. J. Pharmacol. Exp. Ther. 178: 464-73.
38. Loesberg, C., Van Rouij, H., Nooijen, W. J., Meijer, A. J., and Smets, L. A. 1990. Impaired mitochondrial respiration and stimulated glycolysis by m-iodobenzylguanidine (MIBG). Int. J. Cancer 46: 276-81.
39. Mairs, R. J., Russel, J., Cunningham, S. et al. 1995. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I] meta-iodobenzylguanidine: Implications for the targeted radiotherapy of neuroblastoma. Eur. J. Cancer Res. 31A: 576-81.
40. Mangner, T. J., Wu, J., and Wieland, D. M. 1982. Solid-phase exchange radioiodination of aryl iodides. Facilitation by ammonium sulfate. J. Org. Chem. 47: 1484-88.
41. Mardon, K., Merlet, P., Syrota, A., and Maziere, B. 1998. Effects of altitude hypoxia on myocardial beta-adrenergic pathway in rats. J. Appl. Physiol. 85: 890-97.
42. Melon, P. G., Nguyen, N., DeGrado, T. R., Mangner, T. J., Wieland, D. M., and Schwaiger, M. 1994. Imaging of cardiac neuronal function after cocaine exposure using carbon-11 hydroxyephedrine and positron emission tomography. J. Am. Coll. Cardiol. 23: 1693-99.
43. Merlet, P., Benvenuti, C., Moyse, D. et al. 1999. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J. Nucl. Med. 40: 917-23.
44. Merlet, P., Delforge, J., Syrota, A. et al. 1993. Positron emission tomography with 11C CGP-12177 to assess β-adrenergic receptor concentration in idiopathic dilated cardiomyopathy. Circulation 87: 1169-78.
45. Merlet, P., Valette, H., Dubois-Randé, J.-L. et al. 1992. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J. Nucl. Med. 33: 471-77.
46. Mislankar, S. G., Gildersleeve, D. L., Wieland, D. M., Massin, C. C., Mulholland, G. K., and Toorongian, S. A. 1988. 6-[18F] Fluorometaraminol: A radiotracer for in vivo mapping of adrenergic nerves of the heart. J. Med. Chem. 31: 362-66.
47. Morales, J. O., Beierwaltes, W. H., Counsell, R. E., and Meier, D. H. 1967. The concentration of radioactivity from labeled epinephrine and its precursors in the dog adrenal medulla. J. Nucl. Med. 8: 800-09.
48. Nagahara, D., Nakata, T., Hashimoto, A. et al. 2008. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J. Nucl. Med. 49: 225-33.
49. Nagamatsu, H., Momose, M., Kobayashi, H., Kusakabe, K., and Kasanuki, H. 2007. Prognostic value of 123I-metaiodobenzylguanidine in patients with various heart diseases. Ann. Nucl. Med. 21: 513-20.
50. Nakajo, M., Shimabukuro, K., Yoshimura, H. et al. 1986. Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J. Nucl. Med. 27: 84-89.
51. Nomura, Y., Matsunari, I., Takamatsu, H. et al. 2006. Quantitation of cardiac sympathetic innervation in rabbits using 11C-hydroxyephedrine PET: Relation to 123I-MIBG uptake. Eur. J. Nucl. Med. Mol. Imaging 33: 871-78.
52. Nori, S. L., Gaudino, M., Alessandrini, F., Bronzetti, E., and Santarelli, P. 1995. Immunohistochemical evidence of sympathetic denervation and reinnervation after necrotic injury in rat myocardium. Cell Mol. Biol. 41: 799-807.
53. Pacholczyk, T., Blakely, R. D., and Amara, S. G. 1991. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 350: 350-54.
54. Packer, M. 1992. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. J. Am. Coll. Cardiol. 20: 248-54.
55. Pissarek, M., Ermert, J., Oesterreich, G., Ing, D., Bier, D., and Coenen, H. H. 2002. Relative uptake, metabolism, and β-receptor binding of (1R, 2S)-4-18F-fluorometaraminol and 123I-MIBG in normotensive and spontaneously hypertensive rats. J. Nucl. Med. 43: 366-73.
56. Pop-Busui, R. 2010. Cardiac autonomic neuropathy in diabetes: A clinical perspective. Diabetes Care 33: 434-41.
57. Raffel, D., Loc’h, C., Mardon, K., Mazière, B., and Syrota, A. 1998. Kinetics of the norepinephrine analog [Br-76]-metabromobenzylguanidine in isolated working rat heart. Nucl. Med. Biol. 25: 1-16.
58. Raffel, D. M. and Chen, W. 2004. Binding of [3H]mazindol to cardiac norepinephrine transporters: Kinetic and equilibrium studies. Naunyn-Schmiedeberg’s Arch. Pharmacol. 370: 9-16.
59. Raffel, D. M., Chen, W., Sherman, P. S., Gildersleeve, D. L., and Jung, Y. W. 2006a. Dependence of cardiac 11C-metahydroxyephedrine retention on norepinephrine transporter density. J. Nucl. Med. 47: 1490-96.
60. Raffel, D. M., Corbett, J. R., del Rosario, R. B. et al. 1996. Clinical evaluation of carbon-11-phenylephrine: MAO sensitive marker of cardiac sympathetic neurons. J. Nucl. Med. 37: 1923-31.
61. Raffel, D. M., Jung, Y. W., Gildersleeve, D. L. et al. 2007. Radiolabeled phenethylguanidines: Novel imaging agents for cardiac sympathetic neurons and adrenergic tumors. J. Med. Chem. 50: 2078-88.
62. Raffel, D. M., Koeppe, R. A., Little, R. et al. 2006b. PET Measurement of cardiac and nigrostriatal denervation in parkinsonian syndromes. J. Nucl. Med. 47: 1769-77.
63. Raffel, D. M. and Wieland, D. M. 1999. Influence of vesicular storage and monoamine oxidase activity on [11C]phenylephrine kinetics: Studies in isolated rat heart. J. Nucl. Med. 40: 323-30.
64. Raffel, D. M. and Wieland, D. M. 2001. Assessment of cardiac sympathetic nerve integrity with positron emission tomography. Nucl. Med. Biol. 28: 541-59.
65. Raffel, D. M. and Wieland, D. M. 2010. Development of mIBG as a cardiac innervation imaging agent. JACC Cardiovasc. Imaging 3: 111-16.
66. Raisman, R., Sette, M., Pimoule, C., Briley, M., and Langer, S. Z. 1982. High-affinity [3H]desipramine binding in the peripheral and central nervous system: A specific site associated with the neuronal uptake of noradrenaline. Eur. J. Pharmacol. 78: 345-51.
67. Rosenspire, K. C., Haka, M. S., Van Dort, M. E. et al. 1990. Synthesis and preliminary evaluation of carbon-11-meta-hydroxyephedrine: A false transmitter agent for heart neuronal imaging. J. Nucl. Med. 31: 1328-34.
68. Schömig, E., Fischer, P., Schönfeld, C.-L., and Trendelenburg, U. 1989. The extent of neuronal re-uptake of 3H-noradrenaline in isolated vasa deferentia and atria of the rat. Naunyn-Schmiedeberg’s Arch. Pharmacol. 340: 520-08.
69. Schömig, E., Korber, M., and Bönisch, H. 1988. Kinetic evidence for a common binding site for substrates and inhibitors of the neuronal noradrenaline carrier. Naunyn-Schmiedeberg’s Arch. Pharmacol. 337: 626-32.
70. Schwaiger, M., Kalff, V., Rosenspire, K. et al. 1990. Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography. Circulation 82: 457-64.
71. Schwartz, P. J. 1998. The autonomic nervous system and sudden death. Eur. Heart J. 19(Suppl. F): F72-F80.
72. Sisson, J. C. 2000. Radiopharmaceuticals for nuclear endocrinology at the University of Michigan. Cancer Biother. Radiopharm. 15: 305-18.
73. Sisson, J. C., Wieland, D. M., Sherman, P., Mangner, T. J., Tobes, M. C., and Jacques, S., Jr. 1987. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J. Nucl. Med. 28: 1620-24.
74. Stevens, M. J., Raffel, D. M., Allman, K. C. et al. 1998. Cardiac sympathetic dysinnervation in diabetes: Implications for enhanced cardiovascular risk. Circulation 98: 961-68.
75. Überfuhr, P., Ziegler, S., Schwaiblmair, M., Reichart, B., and Schwaiger, M. 2000. Incomplete sympathetic reinnervation of the orthotopically transplanted human heart: Observation up to 13 years after heart transplantation. Eur. J. Cardiothorac. Surg. 17: 161-68.
76. Ungerer, M., Hartmann, F., Karoglan, M. et al. 1998. Regional in vivo and in vitro characterization of autonomic innervation in cardiomyopathic human heart. Circulation 97: 174-80.
77. Vaidyanathan, G. and Zalutsky, M. R. 1993. No-carrier-added synthesis of meta-[131I]iodobenzylguanidine. Appl. Radiat. Isot. 44: 621-28.
78. Van Dort, M. E., Kim, J. H., Tluczek, L., and Wieland, D. M. 1997. Synthesis of carbon-11 labeled desipramine and its metabolite 2-hydroxydesipramine: Potential radiotracers for PET studies of the norepinephrine transporter. Nucl. Med. Biol. 24: 707-11.
79. Virmani, R., Burke, A. P., and Farb, A. 2001. Sudden cardiac death. Cardiovasc. Pathol. 10: 275-82.
80. Waller, C., Kahler, E., Hiller, K.-H. et al. 2000. Myocardial perfusion and intracapillary blood volume in rats at rest and with coronary dilation: MR imaging in vivo with use of spin-labeling technique. Radiology 215: 189-97.
81. Wei, K., Le, E., Bin, J.-P., Coggins, M., Jayawera, A. R., and Kaul, S. 2001. Mechanism of reversible 99mTc-sestamibi perfusion defects during pharmacologically induced vasodilation. Am. J. Physiol. Heart Circ. Physiol. 280: H1896-H904.
82. Wieland, D. M., Brown, L. E., Rogers, W. L. et al. 1981. Myocardial imaging with a radioiodinated norepinephrine storage analog. J. Nucl. Med. 22: 22-31.
83. Wieland, D. M., Rosenspire, K. C., Hutchins, G. D. et al. 1990. Neuronal mapping of the heart with 6-[18F]fluorometaraminol. J. Med. Chem. 33: 956-64.
84. Wieland, D. M., Swanson, D. P., Brown, L. E., and Beierwaltes, W. H. 1979. Imaging the adrenal medulla with an I-131-labeled antiadrenergic agent. J. Nucl. Med. 20: 155-58.
85. Wieland, D. M., Wu, J., Brown, L. E., Mangner, T. J., Swanson, D. P., and Beierwaltes, W. H. 1980. Radiolabeled adrenergic neuronblocking agents: Adrenomedullary imaging with [131I]iodobenzylguanidine. J. Nucl. Med. 21: 349-53.
86. Zipes, D. P. 1995. In Cardiac Electrophysiology: From Cell to Bedside (Eds, Zipes, D. P. and Jalife, J.) W.B. Saunders, Philadelphia, PA, pp. 441-53.